Hospital
Centennial Hills Hospital Medical Center
Centennial Hills Hospital Medical Center was paid $25.11M by Medicaid between Jan 2018 and Dec 2024, across 262 billing codes. Its largest line is 99285, emergency room visit (most serious) — 20% of everything it billed.
33Billing provider infoCENTENNIAL HILLS HOSPITAL MEDICAL CENTER
LAS VEGAS, NV 89149
LAS VEGAS, NV 89149
33aNPI1487771812assigned 03/22/2007
33bProvider typeGeneral Acute Care Hospital
28Total paid$25.11M
24GClaims1,230,168
24DCodes billed262
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Nevada
Rank by total paid#9 of 36
Median peer was paid$7.64M
This provider vs. median3.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official FILTON, STEVE controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 82,848 | $1.14M | |
| 2019 | 226,367 | $4.29M | |
| 2020 | 185,421 | $3.42M | |
| 2021 | 201,465 | $4.16M | |
| 2022 | 187,112 | $4.18M | |
| 2023 | 193,227 | $4.28M | |
| 2024incomplete | 153,728 | $3.63M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 20% | 46,972 | 38,742 | $5.11M |
| G0378 | Hospital observation service, per hour | 9.8% | 20,654 | 14,593 | $2.45M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 8.9% | 26,148 | 23,194 | $2.23M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 8.6% | 9,313 | 7,888 | $2.15M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 5.2% | 25,368 | 21,398 | $1.30M |
| 70450 | Computed tomography, head or brain; without contrast material | 3.3% | 10,011 | 8,333 | $834K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 2.9% | 3,035 | 2,560 | $725K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2.8% | 4,760 | 4,086 | $699K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.3% | 36,309 | 28,016 | $588K |
| 96361 | Intravenous infusion, hydration; each additional hour | 2.2% | 26,975 | 19,610 | $550K |
| 96375 | Therapeutic injection; each additional sequential IV push | 2.1% | 30,332 | 21,204 | $532K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | 1.6% | 911 | 755 | $411K |
250 more codes
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.2% | 13,080 | $289K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 7,120 | $246K |
| 59025 | Fetal non-stress test | <1% | 6,739 | $234K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 17,262 | $234K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 14,392 | $230K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 71,387 | $217K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 2,074 | $216K |
| 96376 | <1% | 15,444 | $213K | |
| 80053 | Comprehensive metabolic panel | <1% | 47,569 | $203K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 6,614 | $203K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 2,858 | $169K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 5,502 | $157K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 34,847 | $154K |
| 71045 | Radiologic examination, chest; single view | <1% | 24,258 | $148K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 2,148 | $146K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,337 | $142K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 3,389 | $140K |
| 76830 | Ultrasound, transvaginal | <1% | 1,984 | $139K |
| 84484 | <1% | 32,469 | $136K | |
| 76801 | <1% | 2,331 | $135K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,572 | $126K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 9,157 | $118K |
| 84702 | <1% | 20,274 | $116K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 85,613 | $115K |
| 0450 | Emergency room services | <1% | 2,317 | $113K |
| 70496 | <1% | 355 | $109K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 513 | $105K |
| 95819 | <1% | 650 | $103K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,542 | $93K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 411 | $90K |
| 70498 | <1% | 344 | $82K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 26,063 | $82K |
| 93971 | <1% | 1,780 | $81K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 7,522 | $77K |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 894 | $68K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 1,198 | $67K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 2,343 | $66K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 2,198 | $66K |
| 72131 | <1% | 506 | $65K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,806 | $65K |
| 83690 | <1% | 21,098 | $61K | |
| 83880 | <1% | 5,581 | $60K | |
| 97161 | <1% | 2,496 | $60K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 3,244 | $58K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 21,513 | $56K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 1,169 | $56K |
| 93970 | <1% | 719 | $53K | |
| 83605 | <1% | 10,724 | $44K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 888 | $44K |
| 97165 | <1% | 1,759 | $43K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 12,116 | $41K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 3,081 | $40K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,779 | $40K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 433 | $40K |
| 81001 | <1% | 28,952 | $39K | |
| 90715 | <1% | 995 | $38K | |
| 73564 | <1% | 1,838 | $37K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,456 | $35K |
| 47562 | <1% | 29 | $34K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 3,622 | $34K |
| 97162 | <1% | 1,218 | $31K | |
| 85730 | <1% | 15,930 | $30K | |
| 83735 | <1% | 13,618 | $28K | |
| 70486 | <1% | 240 | $28K | |
| 81025 | <1% | 11,529 | $28K | |
| 87040 | <1% | 6,306 | $27K | |
| 85379 | <1% | 6,459 | $27K | |
| J0153 | Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | <1% | 470 | $26K |
| 73630 | <1% | 1,608 | $25K | |
| 73610 | <1% | 1,401 | $25K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 313 | $24K |
| 85610 | <1% | 19,037 | $23K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 6,254 | $22K |
| 73130 | <1% | 1,162 | $20K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,208 | $20K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,205 | $20K |
| 47563 | <1% | 14 | $17K | |
| 73030 | <1% | 1,290 | $17K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,145 | $17K |
| 97166 | <1% | 644 | $17K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 8,501 | $16K |
| 80076 | <1% | 5,036 | $16K | |
| 93017 | <1% | 949 | $15K | |
| 87186 | <1% | 4,257 | $15K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 12,011 | $14K |
| 73110 | <1% | 667 | $14K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 517 | $14K |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 1,492 | $13K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 1,242 | $13K |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | <1% | 241 | $12K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,598 | $12K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 974 | $12K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 8,477 | $12K |
| 80061 | Lipid panel | <1% | 2,946 | $11K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 30,427 | $11K |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 1,688 | $11K |
| 82962 | <1% | 16,076 | $11K | |
| 43235 | <1% | 44 | $11K | |
| 87641 | <1% | 1,732 | $10K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 983 | $10K |
| 82550 | <1% | 4,091 | $10K | |
| 81003 | <1% | 10,858 | $10K | |
| 84145 | <1% | 1,038 | $10K | |
| 72100 | <1% | 656 | $10K | |
| 70491 | <1% | 57 | $9K | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 2,446 | $9K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 503 | $9K |
| 85027 | <1% | 7,211 | $8K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 12,201 | $8K |
| 74018 | <1% | 798 | $8K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,925 | $8K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 44 | $7K |
| 82803 | <1% | 1,114 | $7K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 5,423 | $7K |
| 97116 | <1% | 845 | $7K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,721 | $7K |
| 86140 | <1% | 3,268 | $6K | |
| 74174 | <1% | 12 | $6K | |
| 86901 | <1% | 6,959 | $6K | |
| 87077 | <1% | 1,522 | $6K | |
| 86900 | <1% | 6,850 | $6K | |
| 97597 | <1% | 627 | $6K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 9,881 | $6K |
| J2704 | Injection, propofol, 10 mg | <1% | 9,521 | $6K |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 948 | $5K |
| 80069 | <1% | 2,884 | $5K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 6,722 | $5K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 72 | $5K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,462 | $5K |
| 86850 | <1% | 5,119 | $5K | |
| 74022 | <1% | 203 | $5K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 6,708 | $5K |
| 87210 | <1% | 2,061 | $4K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 5,379 | $4K |
| 84439 | <1% | 1,172 | $4K | |
| 82330 | <1% | 735 | $3K | |
| 84100 | <1% | 2,119 | $3K | |
| 94644 | <1% | 158 | $3K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 51 | $3K |
| 73080 | <1% | 170 | $3K | |
| 93880 | <1% | 36 | $3K | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 2,580 | $3K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 86 | $3K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 5,058 | $3K |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,423 | $3K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 3,086 | $3K |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 87 | $3K |
| 84132 | <1% | 2,736 | $3K | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 2,088 | $2K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 123 | $2K |
| 96367 | <1% | 154 | $2K | |
| J3490 | Unclassified drugs | <1% | 202 | $2K |
| 82140 | <1% | 452 | $2K | |
| 87276 | <1% | 512 | $2K | |
| 87275 | <1% | 512 | $2K | |
| 29125 | <1% | 64 | $2K | |
| 73502 | <1% | 95 | $2K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 730 | $2K |
| 72040 | <1% | 111 | $2K | |
| 87631 | <1% | 1,121 | $1K | |
| 87070 | <1% | 710 | $1K | |
| 76775 | <1% | 66 | $1K | |
| 87205 | <1% | 1,192 | $1K | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 1,050 | $1K |
| 85652 | <1% | 1,456 | $1K | |
| 82607 | <1% | 318 | $1K | |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 201 | $1K |
| 82728 | <1% | 283 | $1K | |
| 84112 | <1% | 90 | $1K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 17 | $1K |
| 82570 | <1% | 504 | $1K | |
| 84295 | <1% | 953 | $1K | |
| 73590 | <1% | 99 | $1K | |
| 85018 | <1% | 1,898 | $1K | |
| 85014 | <1% | 1,840 | $1K | |
| 12001 | <1% | 27 | $986.36 | |
| J0456 | Injection, azithromycin, 500 mg | <1% | 328 | $980.52 |
| 82746 | <1% | 245 | $969.06 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 504 | $911.62 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 1,154 | $910.67 |
| 84550 | <1% | 401 | $857.19 | |
| 85384 | <1% | 534 | $852.45 | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 18 | $798.99 |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 216 | $775.38 |
| 92610 | <1% | 29 | $714.61 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 156 | $695.57 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 6,626 | $665.47 |
| 87563 | <1% | 42 | $653.58 | |
| 87081 | <1% | 365 | $650.38 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 422 | $632.60 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 358 | $623.96 |
| 87430 | <1% | 164 | $607.42 | |
| 80074 | <1% | 80 | $604.94 | |
| 87420 | <1% | 125 | $603.02 | |
| 71101 | <1% | 26 | $581.40 | |
| 94664 | <1% | 59 | $545.50 | |
| 82010 | <1% | 127 | $534.43 | |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | <1% | 29 | $531.10 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 574 | $511.81 |
| 12011 | <1% | 12 | $481.46 | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 148 | $466.53 |
| 73090 | <1% | 35 | $457.06 | |
| 84156 | <1% | 290 | $455.34 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 582 | $430.68 |
| Q0114 | Fern test | <1% | 32 | $392.14 |
| J7510 | Prednisolone oral, per 5 mg | <1% | 16 | $375.46 |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 139 | $307.75 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 57 | $300.62 |
| 83615 | <1% | 133 | $283.20 | |
| 86038 | <1% | 74 | $283.12 | |
| J0692 | Injection, cefepime hydrochloride, 500 mg | <1% | 57 | $278.01 |
| 82731 | <1% | 18 | $256.04 | |
| 0250 | <1% | 96 | $253.98 | |
| G0008 | Administration of influenza virus vaccine | <1% | 48 | $253.80 |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 20 | $252.57 |
| 82553 | <1% | 47 | $252.16 | |
| 90686 | <1% | 47 | $210.47 | |
| A9270 | Non-covered item or service | <1% | 15,470 | $209.97 |
| C1769 | Guide wire | <1% | 195 | $155.27 |
| J3105 | Injection, terbutaline sulfate, up to 1 mg | <1% | 42 | $135.15 |
| J1836 | Injection, metronidazole, 10 mg | <1% | 282 | $114.45 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 109 | $76.60 |
| 83986 | <1% | 62 | $76.43 | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 15 | $68.66 |
| 82150 | <1% | 31 | $67.62 | |
| 93356 | <1% | 19 | $64.11 | |
| J2800 | Injection, methocarbamol, up to 10 ml | <1% | 105 | $63.77 |
| 86780 | <1% | 12 | $63.75 | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 49 | $54.30 |
| J0694 | Injection, cefoxitin sodium, 1 gm | <1% | 14 | $50.24 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 728 | $38.37 |
| 88304 | <1% | 68 | $33.66 | |
| 85046 | <1% | 22 | $26.73 | |
| J1920 | Injection, labetalol hydrochloride, 5 mg | <1% | 77 | $16.53 |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | <1% | 27 | $14.00 |
| 83540 | <1% | 13 | $11.67 | |
| J0736 | Injection, clindamycin phosphate, 300 mg | <1% | 17 | $10.75 |
| 83550 | <1% | 12 | $9.56 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 178 | $5.49 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 228 | $0.95 |
| Q0177 | Hydroxyzine pamoate, 25 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 12 | $0.72 |
| 0353U | 0% | 314 | $0.00 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 306 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 307 | $0.00 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 43 | $0.00 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 55 | $0.00 |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 116 | $0.00 |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 118 | $0.00 |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 118 | $0.00 |
| G0257 | Unscheduled or emergency dialysis treatment for an esrd patient in a hospital outpatient department that is not certified as an esrd facility | 0% | 26 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialFILTON, STEVE (CFO, SENIOR VP)
| Provider | Location | Paid |
|---|---|---|
| District Hospital Partners L P | Washington, DC | $136.25M |
| Mcallen Hospitals L P | Edinburg, TX | $124.61M |
| Lancaster Hospital Corporation | Palmdale, CA | $108.63M |
| Universal Health Services of Rancho Springs INC | Murrieta, CA | $61.95M |
| Doctors Hospital of Laredo | Laredo, TX | $52.31M |
| Valley Hospital Medical Center | Las Vegas, NV | $47.03M |
| Northwest Texas Healthcare System INC | Amarillo, TX | $44.81M |
| Uhs of Bowling Green LLC | Bowling Green, KY | $41.21M |
| Uhs-Corona INC | Corona, CA | $35.18M |
| Spring Valley Medical Center | Las Vegas, NV | $33.58M |
| Aiken Regional Medical Centers LLC | Aiken, SC | $31.51M |
| Summerlin Hospital Medical Center L L C | Las Vegas, NV | $30.26M |
| Manatee Memorial Hospital L P | Bradenton, FL | $22.33M |
| Desert Springs Hospital | Las Vegas, NV | $22.29M |
| Fort Duncan Medical Center LP | Eagle Pass, TX | $15.80M |
| Psi Pride Institute INC | Eden Prairie, MN | $15.57M |
| Uhs of Fuller INC | S Attleboro, MA | $13.47M |
| Uhs of Texoma, INC | Denison, TX | $12.51M |
| Arbour INC | Boston, MA | $12.36M |
| Wellington Regional Medical Center LLC | Wellington, FL | $10.75M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.